HIMS · Hims & Hers Health, Inc.
One customer — 10% of receivables (December 31, 2025)
“As of December 31, 2025, one customer or partner individually represented more than 10% of accounts receivable.”
4 customers — 10% of receivables (December 31, 2024)
“As of December 31, 2024, four customers or partners individually represented more than 10% of accounts receivable.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HIMS
this stock
Hims & Hers Health, Inc.
|
$6.51B | -14.1% | +59.0% | — | 23.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$59.80B | +22.2% | — | — | 0.1% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.49B | +25.6% | +4.3% | 64.0 | 3.2% |
|
GALDY
Galderma Group AG/ADR
|
$44.48B | -8.0% | — | — | 0.0% |
|
HLN
Haleon plc
|
$41.16B | -7.4% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HIMS | +1.6% | -10.3% | +33.7% | -5.7% | -14.1% |
| SPY | +0.6% | -0.8% | +18.2% | -0.6% | +11.8% |
| vs SPY | +1.0% | -9.5% | +15.5% | -5.1% | -25.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.